Laser photocoagulation, adjuvant bevacizumab preserve contrast in eyes with PDR
Intravitreal bevacizumab injections appeared to mitigate loss of contrast sensitivity resulting from panretinal photocoagulation in eyes with high-risk proliferative diabetic retinopathy, according to a study.
The prospective, randomized study included 70 eyes of 35 patients with high-risk proliferative diabetic retinopathy; 35 eyes underwent panretinal photocoagulation (PRP) alone, and 35 eyes underwent PRP with adjuvant intravitreal injections of Avastin (bevacizumab, Genentech). Mean patient age was 56 years.
Investigators evaluated visual acuity, contrast sensitivity, IOP and digital color fundus images. Stratus optical coherence tomography was used to evaluate foveal thickness.
PRP was performed three times and bevacizumab injections were given twice.
Contrast sensitivity improved significantly at 3 months in eyes that undewent combined PRP and bevacizumab injection, according to the authors. Contrast sensitivity decreased significantly in eyes that underwent PRP alone.
Further study is needed to confirm the results, the authors said.
Disclosure: This study was supported by the Sao Paulo Research Foundation. The study authors report no relevant financial disclosures.